(MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) in type 2 diabetes patients compared with other glucose-lowering therapies, a systematic…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
